Letter to the Editor concerning “Re-irradiation in gynaecological cancers, present experiences and future hopes”

Barcellini, Amelia; Vitolo, Viviana; Mastella, E.; Mirandola, A.; Valvo, Francesca

doi:10.1007/s13566-019-00396-w

Cited by 6 publications

(7 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Besides the favourable dose distribution, CIRT has a variety of documented positive radiobiological features compared to photon radiotherapy, due to the characteristic microscopic distribution of energy deposition. The more considerable energy per particle transferred per unit distance by CIRT determines a higher probability of causing complex double-strand DNA breaks, leading to a more successful cell killing at the tumour site (36)(37)(38). The dosimetric and radiobiological properties of CIRT additively define high doses to the tumour saving at-risk adjacent healthy tissues.…”

Section: Discussionmentioning

confidence: 99%

Re-irradiation With Carbon Ion Radiotherapy for Pelvic Rectal Cancer Recurrences in Patients Previously Irradiated to the Pelvis

Barcellini

Vitolo

Cobianchi

et al. 2020

In Vivo

Self Cite

View full text Add to dashboard Cite

Background/Aim: Re-irradiation of locally recurrent rectal cancer poses challenges due to the proximity of critical organs, such as the bowel. This study aimed at evaluating the safety and efficacy of re-irradiation with Carbon Ion Radiotherapy (CIRT) in rectal cancer patients with local recurrence. Patients and Methods: Between 2014 and 2018, 14 patients were treated at the National Center of Oncological Hadrontherapy (CNAO Foundation) with CIRT for locally recurrent rectal cancer. Results: All patients concluded the treatment. No G≥3 acute/late reaction nor pelvic infections were observed. The 1-year and 2-year local control rates were, 78% and 52%, respectively, and relapse occurred close to the bowel in 6 patients. The 1-year and 2-year overall survival rates were 100% and 76.2% each; while the 1-year and 2-year metastasis free survival rates were 64.3% and 43%. Conclusion: CIRT as re-irradiation for locally recurrent rectal cancer emerges as a safe and valid treatment with an acceptable rate of morbidity of surrounding healthy tissue.

show abstract

Section: Discussionmentioning

confidence: 99%

Re-irradiation With Carbon Ion Radiotherapy for Pelvic Rectal Cancer Recurrences in Patients Previously Irradiated to the Pelvis

Barcellini

Vitolo

Cobianchi

et al. 2020

In Vivo

Self Cite

View full text Add to dashboard Cite

show abstract

“…Further, fractionated SBRT might be more advantageous because it allows the re-oxygenation of hypoxic tumour cells and redistribution of resistant tumour cells into more radiosensitive cell cycle phases. 108 Heavy particles, by protons and carbon ions, are emerging as promising treatment RT modality in radioresistant cancers, [109][110][111][112][113][114][115][116] such as pancreatic tumours. [117][118][119][120][121] Proton therapy, thanks to its intrinsic physical selectivity, allows delivering dose to the target with no exit dose in the beam path.…”

Section: Radiotherapymentioning

confidence: 99%

“…126 Carbon ions are high linear energy transfer (LET) radiations able to deposit higher energy in the target, compared to conventional photons (low LET radiation), producing significantly more DNA damages to malignant cells, because of their higher relative biological effectiveness (RBE). 110,118 Further, the type of damage is different. Whereas photon irradiation leads to indirect DNA damage through the creation of free radicals against the DNA, carbon ion radiotherapy (CIRT) leads to direct DNA damage without an intermediary.…”

Section: Radiotherapymentioning

confidence: 99%

See 1 more Smart Citation

<p>Locally Advanced Pancreatic Ductal Adenocarcinoma: Challenges and Progress</p>

Barcellini¹,

Peloso²,

Pugliese³

et al. 2020

OTT

Self Cite

View full text Add to dashboard Cite

Pancreatic ductal adenocarcinoma (PDAC) is one of the major causes of death in the Western world, and it is estimated to become the second leading cause of tumour-related mortality in the next 10 years. Among pancreatic cancers, ductal adenocarcinomas are by far the most common, characterised by a challenging diagnosis due to the lack of initial and pathognomonic clinical signs. In this scenario, non-metastatic locally advanced pancreatic cancer (LAPC) accounts for a large proportion of all new pancreatic ductal adenocarcinoma diagnoses. There is no consensus on a common definition of LAPC. Still, it usually includes tumours that are not resectable due to vascular involvement. As of today, treatment is limited, and the prognosis is very unfavourable. Curative-intent surgery remains the gold-standard even if often jeopardized by vascular involvement. Continuing progress in our understanding of LAPC genetics and immunology will permit the development of different treatments, targeted or combined, including radiation therapy, hadrontherapy, targeted immunotherapies or new chemotherapies. A multidisciplinary approach combining various fields of expertise is essential in aiming to limit disease progression as well as patient outcome. Using a narrative literature review approach, the manuscript explores the most up-to-date knowledge concerning locally advanced pancreatic ductal adenocarcinoma management.

show abstract

“…Consequently, carbon ion radiotherapy (CIRT) allows delivering a high dose to the target and sparing healthy tissues more than photons. Radiobiologically, carbon ions are characterized by their higher relative biological effectiveness (RBE) compared to photons, act independently from the oxygen effect or from the phase of the cell cycle, and can create clustered and difficult-to-repair DNA damage resulting in an increased probability of cell killing and better effect on radioresistant tumor tissues [74-76]. To the best of our knowledge, there is only one report regarding CIRT for inoperable EC.…”

Section: Role Of Rtmentioning

confidence: 99%

Endometrial Cancer: When Upfront Surgery Is Not an Option

et al. 2020

Self Cite

View full text Add to dashboard Cite

show abstract

Letter to the Editor concerning “Re-irradiation in gynaecological cancers, present experiences and future hopes”

Cited by 6 publications

References 9 publications

Re-irradiation With Carbon Ion Radiotherapy for Pelvic Rectal Cancer Recurrences in Patients Previously Irradiated to the Pelvis

Re-irradiation With Carbon Ion Radiotherapy for Pelvic Rectal Cancer Recurrences in Patients Previously Irradiated to the Pelvis

<p>Locally Advanced Pancreatic Ductal Adenocarcinoma: Challenges and Progress</p>

Endometrial Cancer: When Upfront Surgery Is Not an Option

Contact Info

Product

Resources

About